Company
United StatesPublic company, NASDAQ: CHRSCoherus Oncology, Inc. (NASDAQ: CHRS), Camarillo, CA – FDA Inspections
Inspection records and compliance data for Coherus Oncology, Inc. in Camarillo, California. 1 FDA inspection on record, last inspected July 26, 2018. Publicly traded as NASDAQ: CHRS.
Company Profile
This profile covers Coherus Oncology, Inc. based in Camarillo, California, United States.
FDA Inspection History
- FDA inspections
- 1
- OAI
- 0
- VAI
- 0
- NAI
- 0
- Unclassified
- 1
- Form 483s
- 0
- Warning letters
- 0
Inspected July 26, 2018.
FDA inspections (1)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| July 26, 2018 | Not classified | Human Drugs | 1081605 |
FDA documents
No Form 483s, Warning Letters or EIRs on record.
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
Coherus Oncology, Inc.
Stock ticker
CHRS
Exchange
NASDAQ
Share price
$0.75
Market cap
$115.9M
Price as of
November 6, 2026
FEI Number
3011671070
Address
1000 Avenida Acaso, Camarillo, California 93012-8712, United States
Country
United States
ID: e7c70a55-21e3-4ecd-9323-28a32cd5903f